Login to Your Account



Other News To Note


Thursday, March 3, 2011
OncoMed Pharmaceuticals Inc., of Redwood City, Calif., said preclinical data demonstrated its lead candidate, OMP-21M18, inhibits tumor growth and reduces cancer stem cell frequency when administered alone or in combination with chemotherapy in human colorectal cancer tumors with or without KRAS mutations. The data were published in the March 1, 2011, issue of Cancer Research.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription